603108.SH
润达医疗
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 9.55
−3.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.8B | 7.0B | 8.3B | 9.1B | 10.5B |
| Cost of Revenue | 5.3B | 5.5B | 6.2B | 6.7B | 7.6B |
| Gross Profit | 1.5B | 1.5B | 2.1B | 2.4B | 2.9B |
| Operating Expenses | |||||
| R&D Expense | 108.2M | 108.0M | 116.2M | 147.1M | 146.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 427.3M | 438.5M | 479.9M | 508.8M | 541.3M |
| Selling & Marketing Expense | 727.1M | 748.6M | 840.8M | 913.9M | 1.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.6B | 1.6B | 1.8B | 1.9B | 2.1B |
| Cost and Expenses | 6.9B | 7.1B | 8.0B | 8.7B | 9.6B |
| Operating Income (EBIT) | (436.5M) | (450.3M) | 354.1M | 646.8M | 816.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (447.9M) | (460.6M) | 345.5M | 655.6M | 819.7M |
| Income Tax Expense | 48.3M | 57.5M | 156.1M | 212.9M | 164.5M |
| Bottom Line | |||||
| Net Income | (532.7M) | (548.4M) | 55.3M | 273.3M | 417.7M |
| Earnings from Cont. Ops | (496.3M) | (518.2M) | 189.5M | 442.6M | 655.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (532.7M) | (548.4M) | 55.3M | 273.3M | 417.7M |
| Per Share | |||||
| Basic EPS | (CN¥0.88) | (CN¥0.91) | CN¥0.09 | CN¥0.47 | CN¥0.72 |
| Diluted EPS | (CN¥0.88) | (CN¥0.91) | CN¥0.09 | CN¥0.47 | CN¥0.70 |
| Revenue Per Share | CN¥11.51 | CN¥11.61 | CN¥13.53 | CN¥15.73 | CN¥18.09 |
| Shares | |||||
| Basic Shares Outstanding | 595.1M | 602.6M | 614.2M | 581.5M | 580.2M |
| Diluted Shares Outstanding | 595.1M | 602.6M | 614.2M | 581.5M | 580.2M |
| Profitability Metrics | |||||
| EBITDA | — | (113.7M) | 719.8M | 990.6M | 1.2B |
| D&A | — | 336.5M | 365.8M | 343.8M | 338.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026